SLC10A2 and congenital secretory chloride diarrhea 1: Several ASBT inhibitor drugs, such as Odevixibat, Maralixibat, and Linerixibat, have been utilized in phase II and phase III clinical trials targeting pediatric CLD (Table 2) (Baumann et al. 2021; Bowlus et al. 2023; Gonzales et al. 2021; Hegade et al. 2017; Levy et al. 2023; Loomes et al. 2022; Thompson et al. 2022).